Regional subgroup analysis of the Phase III TOPAZ-1 clinical trial of durvalumab (D) plus gemcitabine and cisplatin (GC) in advanced biliary tract cancer (BTC). (Abstract # 4075) Read More- https://www.delveinsight.com/asco-conference/article/durvalumab-immunotherapy?utm_source=Promotion&utm_medium=ASCO&utm_campaign=ConferenceCoverage